CRC’s poor sensitivity to some of these therapies is likely due to feedback activation of EGFR signaling; simultaneous inhibition of EGFR improves outcomes (Amodio et al. 2020, Kopetz et al. 2019, Yaeger et al. 2023). The gene discussed is EGFR; the disease is colorectal carcinoma.